ZVRA · Zevra Therapeutics, Inc. · Webcasts, Transcripts & Audio
$9.08
-2.08 (-18.64%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$540.30M
Shares
59.50M
Volume · Nov 13
2.94M
Avg daily vol (3M)
942.63K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Zevra Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Zevra Therapeutics, Inc. (ZVRA), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-03
Zevra Therapeutics, Inc. (ZVRA) Q3 2026 Earnings Call Transcript
Revenue
$37.76M
▲ 44.9% YoY Diluted EPS
$0.26
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Zevra Therapeutics, Inc. (ZVRA) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-11
Zevra Therapeutics, Inc. (ZVRA) August 11, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript
Confident tone
European MAA reexamination (CHMP negative opinion)
Capital allocation / business development strategy
Financial strength and cash position
Revenue
$39.66M
▲ 53.3% YoY Diluted EPS
$0.14
▼ 88.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-19
Zevra Therapeutics, Inc. (ZVRA) May 19, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Confident tone
MyPlifer (miglustat/aramcholamol) U.S. launch
Celiprolol DISCOVER Phase III trial for VEDS
Reimbursement and channel dynamics
Revenue
$36.22M
▲ 77.5% YoY Diluted EPS
$0.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-09
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Confident tone
NPC patient identification and diagnosis
European expansion and MAA
MyPlypha commercial performance
Revenue
$34.12M*
▲ 183.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript
Confident tone
MIPLYFFA commercial performance in NPC
Gross-to-net and Medicare Part D adjustment
European expansion and MAA
Revenue
$26.06M
▲ 605.4% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript
Confident tone
European expansion (MAA submission)
Reimbursement / payer coverage
Diagnosis awareness / patient identification
Revenue
$25.88M
▲ 481.7% YoY Diluted EPS
$1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript
Confident tone
Soliprolol / DISCOVER Phase 3 trial
Olpruva (UCDs) commercial strategy
Financial strength / PRV monetization
Revenue
$20.40M
▲ 495.6% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript
Confident tone
Reimbursement and access
Market expansion / patient identification
Financial position and capital allocation
Revenue
$12.04M*
▼ 6.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript
Positive tone
MIPLYFFA launch
European regulatory expansion
Guidance and revenue timing
Revenue
$3.69M
▲ 27.6% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript
Confident tone
Arimoclomol FDA review and PDUFA
Expanded Access Program transition
OLPRUVA launch progress
Revenue
$4.45M
▼ 47.5% YoY Diluted EPS
$-0.48
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Zevra Therapeutics, Inc. (ZVRA) Q1 2024 Earnings Call Transcript
Positive tone
Arimoclomol Regulatory Review
OLPRUVA Commercial Launch
KP1077 in Sleep Disorders
Revenue
$3.42M
▲ 7.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Zevra Therapeutics, Inc. (ZVRA) Q4 2023 Earnings Call Transcript
Positive tone
Arimoclomol NDA and FDA review
OLPRUVA commercial launch
KP1077 in idiopathic hypersomnia
Revenue
$12.92M*
▲ 539% YoY Gross margin
84.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Zevra Therapeutics, Inc. (ZVRA) Q3 2023 Earnings Call Transcript
Revenue
$2.90M
▲ 0.7% YoY Gross margin
95.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Zevra Therapeutics, Inc. (ZVRA) Q2 2023 Earnings Call Transcript
Revenue
$8.47M
▲ 551.5% YoY Gross margin
92.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Zevra Therapeutics, Inc. (ZVRA) Q1 2023 Earnings Call Transcript
Revenue
$3.18M
▼ 19.9% YoY Gross margin
96.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-25
Zevra Therapeutics, Inc. (ZVRA) Q4 2022 Earnings Call Transcript
Revenue
$2.02M*
▼ 21.7% YoY Gross margin
98.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Zevra Therapeutics, Inc. (ZVRA) Q3 2022 Earnings Call Transcript
Revenue
$2.87M
▲ 46.3% YoY Gross margin
95.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-11
Zevra Therapeutics, Inc. (ZVRA) Q2 2022 Earnings Call Transcript
Revenue
$1.30M
▼ 89.2% YoY Gross margin
96.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Zevra Therapeutics, Inc. (ZVRA) Q1 2022 Earnings Call Transcript
Revenue
$3.96M
▼ 67.3% YoY Gross margin
99.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-30
Zevra Therapeutics, Inc. (ZVRA) Q4 2021 Earnings Call Transcript
Revenue
$2.58M*
▲ 9.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-10
Zevra Therapeutics, Inc. (ZVRA) Q3 2021 Earnings Call Transcript
Revenue
$1.97M
▲ 2.1% YoY Diluted EPS
$-0.06
Gross margin
100.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2021 Earnings Call Transcript
Revenue
$11.99M
▲ 73.5% YoY Diluted EPS
$-0.40
▼ 290.5% YoY Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-13
Zevra Therapeutics, Inc. (ZVRA) Q1 2021 Earnings Call Transcript
Revenue
$12.12M
▲ 480% YoY Diluted EPS
$-2.49
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-03-11
Zevra Therapeutics, Inc. (ZVRA) Q4 2020 Earnings Call Transcript
Revenue
$2.37M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Date not confirmed
Zevra Therapeutics, Inc. (ZVRA) Q3 2020 Earnings Call Transcript
Revenue
$1.93M
▼ 83.2% YoY Diluted EPS
$-0.68
▼ 170.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-12
Zevra Therapeutics, Inc. (ZVRA) Q2 2020 Earnings Call Transcript
Revenue
$6.91M
Diluted EPS
$0.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-12
Zevra Therapeutics, Inc. (ZVRA) Q1 2020 Earnings Call Transcript
Revenue
$2.09M
Diluted EPS
$-1.92
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–30 of 30 webcasts
Key facts
CIK
1434647
CUSIP
488445206
13F (30d)
140 filings
117 filers
Visit website
Investor relations